Select Page
Recommendations for unleashing meaningful innovation through regulatory reform

Recommendations for unleashing meaningful innovation through regulatory reform

What do we know when a new medicine is approved? What are the regulatory requirements for new medicines? What happens once a new drug is on the market? Following the first  of the EPHA #A2MDialogues,  our panelists Andrea Cipriani, Lydia Meheus, Huseyin Naci and Beate...
Transparency is needed to reap the full benefits of the EU’s investment in its Vaccines Strategy, say health NGOs

Transparency is needed to reap the full benefits of the EU’s investment in its Vaccines Strategy, say health NGOs

The COVID-19 crisis represents an unprecedented challenge for societies in the European Union as well as at a global level. The European vaccines strategy’s Advance Purchase Agreements (APAs) mechanism has been used by the EU to procure vaccines for COVID-19. We...
Public health must be the leading priority of Europe’s pharmaceutical sector

Public health must be the leading priority of Europe’s pharmaceutical sector

The EU must ensure access to affordable and quality medicines in Europe whilst guaranteeing everyone’s right to a healthy and sustainable environment. Human medicine is not an ordinary commodity – public interest and public health should prevail as leading...
What lies ahead for health under the German Presidency?

What lies ahead for health under the German Presidency?

Germany assumed the Presidency of the Council of the European Union from 1 July, but in quite different circumstances from what was originally foreseen, with the response to tackling COVID-19, and its health, economic and social consequences being the defining issue...